Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00DDX
|
|||
| Drug Name |
N-(pyridin-2-yl)pyrimidin-4-amine derivative 1
|
|||
| Synonyms |
PMID26161698-Compound-24
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
BAYER PHARMA AKTIENGESELLSCHAFT
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H16F4N4O3S
|
|||
| Canonical SMILES |
COC1=C(C=CC(=C1)F)C2=CC(=NC=N2)NC3=CC(=CC(=N3)C(F)(F)F)CS(=O)(=O)C
|
|||
| InChI |
1S/C19H16F4N4O3S/c1-30-15-7-12(20)3-4-13(15)14-8-17(25-10-24-14)27-18-6-11(9-31(2,28)29)5-16(26-18)19(21,22)23/h3-8,10H,9H2,1-2H3,(H,24,25,26,27)
|
|||
| InChIKey |
WUAZMKUDCHZMEP-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cyclin-dependent kinase 9 (CDK9) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Cyclin-dependent kinase 9 (CDK9) | Target's Patent Info | [1] | |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| Reactome | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | |||
| WikiPathways | Cardiac Hypertrophic Response | |||
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | ||||
| Host Interactions of HIV factors | ||||
| HIV Life Cycle | ||||
| IL-9 Signaling Pathway | ||||
| RNA Polymerase II Transcription | ||||
| MicroRNAs in cardiomyocyte hypertrophy | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.